Pharming Group DB:PHG Stock Report Company Financials + 4 Analysts
Pharming Group N.V.
DB:PHG Stock Report
PHG Stock Overview A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.
Rewards Risk Analysis No risks detected for PHG from our risk checks.
See All Risk Checks Pharming Group N.V. Competitors Price History & Performance
Summary of all time highs, changes and price drops for Pharming Group Historical stock prices Current Share Price €7.05 52 Week High €11.70 52 Week Low €6.00 Beta 0.81 11 Month Change -4.73% 3 Month Change 1.44% 1 Year Change -30.20% 33 Year Change -7.84% 5 Year Change n/a Change since IPO -37.97%
Recent News & Updates
Pharming Group Announces Start of Phase II Clinical Trial of Leniolisib for Primary Immunodeficiencies (PIDs) with Immune Dysregulation Oct 10
Pharming Group N.V. Provides Update on Ongoing Regulatory Review of Leniolisib for the Treatment of Apds in the European Union Jun 02
Pharming Group N.V. Provides Revenue Guidance for 2024 May 09 Pharming Group N.V. announced that it expects to receive €100 million in funding Apr 20
Pharming Group N.V. to Report Q2, 2024 Results on Aug 01, 2024
Pharming Group N.V. to Report Q4, 2023 Results on Mar 14, 2024 Dec 19 See more updates
Pharming Group Announces Start of Phase II Clinical Trial of Leniolisib for Primary Immunodeficiencies (PIDs) with Immune Dysregulation Oct 10
Pharming Group N.V. Provides Update on Ongoing Regulatory Review of Leniolisib for the Treatment of Apds in the European Union Jun 02
Pharming Group N.V. Provides Revenue Guidance for 2024 May 09 Pharming Group N.V. announced that it expects to receive €100 million in funding Apr 20
Pharming Group N.V. to Report Q2, 2024 Results on Aug 01, 2024
Pharming Group N.V. to Report Q4, 2023 Results on Mar 14, 2024 Dec 19
Pharming Group N.V. Appoints Richard Peters as Non-Executive Director Sep 26
Pharming Group N.V. Announces First Patient Enrolled in Phase Iii Clinical Trial of Leniolisib for the Treatment of Apds in Japan Aug 09
Pharming Group N.V. Appoints Alexander Breidenbach as Chief Business Officer Aug 03
Pharming Group N.V. Approves the Proposal to Reappoint Paul Sekhri, Chair of the Board, as Non-Executive Director for A Period of One Year Who Will Resign from the Board Upon Appointment of His Successor May 18
Pharming Group N.V. Provides Update on EMA Regulatory Review of Leniolisib for Apds in Europe Feb 18
Pharming Group N.V. Announces Positive Interim Analysis Data from Open-Label Extension Study of Leniolisib in Presentation At the 64Th American Society of Hematology (ASH) Annual Meeting and Exposition Dec 15 Pharming Group N.V. to Report Fiscal Year 2022 Results on Mar 16, 2023
Pharming Group N.V. Announces Positive Results of Phase 3 Clinical Trial of Investigational Drug Leniolisib Dec 08
Pharming Group N.V. Announces European Medicines Agency Validates its Marketing Authorisation Application Under Accelerated Assessment for Leniolisib Oct 29
Pharming Group N.V. Submits Marketing Authorisation Application to European Medicines Agency for Leniolisib Oct 11
Pharming Group N.V. Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib Sep 28
Pharming Announces New ICD-10-CM Code for APDS, a Rare Primary Immunodeficiency Aug 02
Pharming Group N.V. Receives Accelerated Assessment in Europe for Leniolisib for the Treatment of Rare Immunodeficiency, APDS Aug 01 GIMV NV (ENXTBR:GIMB) completed the acquisition of 20.87% stake in Bioconnection B.V. from Pharming Group N.V. (ENXTAM:PHARM). May 13
Pharming Receives Agreement of Paediatric Investigation Plan and Promising Innovative Medicine Designation for Leniolisib from UK MHRA Apr 26 GIMV NV (ENXTBR:GIMB) reached an agreement to acquire 20.87% stake in Bioconnection B.V. from Pharming Group N.V. (ENXTAM:PHARM) for ?6.9 million. Apr 23
Pharming Group N.V. Announces Positive Data from Phase II/III Leniolisib Trial Presented at Clinical Immunology Society 2022 Annual Meeting Apr 03
Pharming Group N.V. Announces Positive Results of Phase II/III Pivotal Clinical Study of Leniolisib for the Treatment of Activated PI3K Delta Syndrome Feb 02
Pharming Receives Positive European Medicines Agency Decision on Paediatric Investigation Plan for Leniolisib in Europe Jan 06
Pharming Announces Results from Clinical Trials for the Treatment of COVID-19 with RUCONEST® Sep 15
Pharming Group N.V Announces Completion of Enrolment in Phase II/III Study with Leniolisib for Activated Pi3k Delta Syndrome Jun 24 Pharming Group N.V. to Report Fiscal Year 2020 Final Results on Apr 06, 2021 Pharming Group N.V. to Report First Half, 2021 Results on Aug 05, 2021 Shareholder Returns PHG DE Biotechs DE Market 7D -2.8% -2.2% 1.1% 1Y -30.2% -17.1% 13.5%
See full shareholder returns
Return vs Market: PHG underperformed the German Market which returned 13.5% over the past year.
Price Volatility Is PHG's price volatile compared to industry and market? PHG volatility PHG Average Weekly Movement 5.7% Biotechs Industry Average Movement 5.8% Market Average Movement 4.7% 10% most volatile stocks in DE Market 10.8% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: PHG has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: PHG's weekly volatility (6%) has been stable over the past year.
About the Company Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Show more Pharming Group N.V. Fundamentals Summary How do Pharming Group's earnings and revenue compare to its market cap? PHG fundamental statistics Market cap €491.47m Earnings (TTM ) -€16.79m Revenue (TTM ) €269.11m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) PHG income statement (TTM ) Revenue US$285.75m Cost of Revenue US$30.30m Gross Profit US$255.44m Other Expenses US$273.26m Earnings -US$17.82m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.026 Gross Margin 89.39% Net Profit Margin -6.24% Debt/Equity Ratio 42.3%
How did PHG perform over the long term?
See historical performance and comparison
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
